Nurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug — BigGo Finance
Nurix Therapeutics (NRIX) shares dropped 35% after Sanofi ended a Phase 1 study of an oral drug licensed from Nurix. The drug, SAR448272, was for inflammatory and autoimmune conditions. Nurix stands to lose $455M in potential milestones and royalties but retains other partnerships and $1.1B in cash. The company's other programs, including bexobrutinib in Phase 3, remain in development.
How this was made
The 30-second read
Why it matters
The termination removes a $455M potential milestone, triggering a sharp sell‑off and forcing investors to reassess valuation models that heavily weighted the Sanofi deal.
Market read
The news directly caused a 35% drop in NRIX shares, highlighting the materiality of partnership milestones for small‑cap biotech valuations.
What to watch
Nurix still retains cash runway into 2029 and other royalty streams; the market may overreact to a single early‑stage setback.
Background
Nurix Therapeutics relies heavily on partnership milestones for cash flow; the Sanofi collaboration accounted for a large portion of expected near‑term revenue.
Ticker impact
Sanofi terminated the Phase 1 oral drug SAR448272, stripping Nurix of a $455M milestone and causing a 34‑35% share drop in extended trading.
likely continued pressure as investors re‑price the lost milestone and focus on other pipeline assets.
The news is the first report of the termination, the stock fell ~35% on the day, and the lost milestone represents a material cash flow expectation.
Market effects
Biotech partnership milestones become riskier, may dampen sentiment toward other early‑stage collaboration deals.
U.S. biotech sector sees modest pullback; European partner Sanofi faces no immediate impact.
Limited to biotech investors; no broader market shift expected.
Counterpoint
The loss may be priced in already; focus on Nurix's remaining pipeline could present upside if bexobrutinib data are positive.
Key entities
- companyNurix Therapeutics, Inc.
U.S. biotech firm developing protein degrader therapies.
- companySanofi
French pharmaceutical giant and partner in the terminated program.
